Biologics are one of the fastest-growing sectors in the pharmaceutical industry , accounting for over 40% of all FDA-approved oncology drugs from 2000 to 2022 and have predominant roles in the development of biomarkers and many other disease treatments. However, the molecular complexity providing their target specificity also makes biologics more vulnerable and less robust than small molecules.